Research programme: anti-Mullerian inhibiting substance type II receptor humanised monoclonal antibodies - GamaMabs Pharma

Drug Profile

Research programme: anti-Mullerian inhibiting substance type II receptor humanised monoclonal antibodies - GamaMabs Pharma

Alternative Names: Anti-AMHRII humanised monoclonal antibody; Anti-MISRII humanised monoclonal antibody 12G4; GM103; hmAb 12G4; Humanised monoclonal antibody 12G4

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institut de Recherche en Cancerologie de Montpellier
  • Developer GamaMabs Pharma
  • Class Monoclonal antibodies
  • Mechanism of Action Anti-Mullerian hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Ovarian cancer

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Ovarian-cancer in France (Parenteral)
  • 21 Apr 2018 Pharmacodynamics data from preclinical studies in Ovarian cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 30 Sep 2013 Preclinical trials in Ovarian cancer in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top